EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review

Yi Li iD, Hongyu Gao, Jinghui Zhao, Liqing Ma, Dan Hu

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0297854 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, 2024. Verfasst von Yi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, No 1 Hospital Of Baoding, Baoding, Hebei, China. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Bempedoic acid, an innovative oral medication, has garnered significant interest in recent times due to its potential as a therapeutic intervention for hypercholesterolemia. Nonetheless, the outcomes of the initial investigations might have been more definitive and coherent. Our objective was to perform a quantitative meta-analysis in order to evaluate bempedoic acid’s safety and effectiveness.

Methods

A search was conducted on ClinicalTrials.gov, and PubMed from the time of inception until September 28, 2023. Randomized controlled trials comparing the safety and efficacy of bempedoic acid among patients with statin intolerance and those without were included in our analysis. The trial outcomes were summarized using a random effects model and were provided as mean differences or odds ratios (ORs) with a confidence interval of 95%. Additionally, trial heterogeneity and the possibility of bias were evaluated and investigated.

Results

Bempedoic acid treatment reduced low-density lipoprotein cholesterol levels more than placebo (mean difference -2.97%, 95% CI -5.89% to -0.05%), according to a pooled analysis of 16 eligible trials. The risk of death (OR 1.18, 95% CI 0.70 to 1.98) and muscle-associated occurrences (OR 1.00, 95% CI 0.77 to 1.31) was not impacted by bempedoic acid. In contrast, discontinuation of treatment was more frequently caused by adverse events in the bempedoic acid group (OR 1.13, 95% CI 1.01 to 1.27).

Conclusions

In patients with statin intolerance as well as those without, bempedoic acid is a safe and efficacious lipid-lowering agent, according to findings from randomized controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHumansDicarboxylic AcidsFatty AcidsHypolipidemic AgentsRandomized Controlled Trials as Topic

Substanzen

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsFatty AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic Agents

Autor:innen und Institutionen

  • Department of Cardiology, No 1 Hospital Of Baoding, Baoding, Hebei, China.

ORCID-Profile: Yi Li

Zitieren

APA

Li, Y., Gao, H., Zhao, J., Ma, L., & Hu, D. (2024). Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review. PLOS ONE. https://doi.org/10.1371/journal.pone.0297854

Vancouver

Li Y, Gao H, Zhao J, Ma L, Hu D. Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review. PLOS ONE. 2024. doi:10.1371/journal.pone.0297854

BibTeX
@article{Li2024,
  author = {Li, Yi and Gao, Hongyu and Zhao, Jinghui and Ma, Liqing and Hu, Dan},
  title = {Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0297854}
}
Kostenlos starten →